Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
Lantern Pharma, an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary […]
Lantern Pharma Announces First Patient Dosed in Study for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
Lantern Pharma, a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning […]
Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors
Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform […]
Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development Collaborations
Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more